Simulations Plus Inc (SLP) 8.87 $SLP Simulations Plus

New Post Public Reply Private Reply Replies (0) Message Board

Sep 22, 2016 at 5:10 PM

Simulations Plus Inc (SLP) 8.87 $SLP

Simulations Plus Reports Preliminary Revenues for Fourth Quarter and Fiscal Year 2016
BusinessWire - Mon Sep 12, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its fiscal fourth quarter (4QFY16) and full fiscal year 2016 (FY2016) ended August 31, 2016.
SLP: 8.87 (+0.50)

Simulations Plus Releases PKPlus(TM) Version 1.0
BusinessWire - Thu Aug 25, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released version 1.0 of PKPlus, its next-generation software for analysis of preclinical and clinical trial data.
SLP: 8.87 (+0.50)

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share
BusinessWire - Mon Aug 01, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Thursday, August 18, 2016, to shareholders of record as of Thursday, August 11, 2016.
SLP: 8.87 (+0.50)

Simulations Plus Releases ADMET Predictor(TM) Version 8.0
BusinessWire - Mon Aug 01, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 8.0 of its best-in-class ADMET Predictor(TM) molecular property prediction software.
SLP: 8.87 (+0.50)

Simulations Plus Reports Preliminary Revenues for Third Quarter FY2016
BusinessWire - Tue Jun 07, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for the third quarter of its fiscal year 2016, the period ended May 31, 2016 (3QFY16).
SLP: 8.87 (+0.50)

Simulations Plus to Present at LD Micro Invitational on June 7, 2016
BusinessWire - Thu Jun 02, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development, announced that Walt Woltosz, chief executive officer, will present at the 6th Annual LD Micro Invitational investor conference on Tuesday, June 7, 2016, at 11:30 a.m. PT. The conference will be held June 7-9, 2016, at the Luxe Sunset Bel Air Hotel in Los Angeles.
SLP: 8.87 (+0.50)

Simulations Plus (SLP): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:12AM CDT
Simulations Plus, Inc. (SLP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
SLP: 8.87 (+0.50)

Simulations Plus Releases DDDPlus Version 5.0
BusinessWire - Thu Apr 14, 7:30AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 5.0 of its DDDPlus(TM) in vitro dissolution experiment simulation software.
SLP: 8.87 (+0.50)

Simulations Plus posts 2Q profit
Automated Insights - Wed Apr 13, 3:06PM CDT
LANCASTER, Calif. (AP) _ Simulations Plus Inc. (SLP) on Wednesday reported fiscal second-quarter profit of $1.1 million.
SLP: 8.87 (+0.50)

Simulations Plus Reports Second Quarter FY2016 Financial Results
BusinessWire - Wed Apr 13, 3:01PM CDT
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2016, the period ended February 29, 2016 (2QFY16).
SLP: 8.87 (+0.50)

Simulations Plus (SLP): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:37AM CST
Simulations Plus is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
SLP: 8.87 (+0.50)

Shares of SLP Up 17.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 01, 5:21PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on December 29th, 2015 at $9.62. In approximately 1 month, Simulations Plus has returned 17.42% as of today's recent price of $11.29.
SLP: 8.87 (+0.50)

Simulations Plus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
BusinessWire - Tue Jan 26, 7:30AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that Walt Woltosz, Chairman and Chief Executive Officer, will provide a company overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Thursday, February 11, 2016, at 8:30 a.m. EST. The conference will be held at the Convene Conference Center at 730 Third Avenue in New York City. Simulations Plus management will be available during the day for one-on-one meetings.
SLP: 8.87 (+0.50)

Uptrend Call Working As Simulations Plus Stock Rises 17.6% (SLP)
Comtex SmarTrend(R) - Mon Jan 25, 12:02PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on December 29th, 2015 at $9.62. In approximately 4 weeks, Simulations Plus has returned 17.63% as of today's recent price of $11.31.
SLP: 8.87 (+0.50)

Simulations Plus Reports First Quarter FY2016 Financial Results
BusinessWire - Thu Jan 14, 3:01PM CST
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2016, the period ended November 30, 2015 (1QFY16).
SLP: 8.87 (+0.50)

New Information Reveals Opportunity in Volatility - Featured Research on Simulations Plus, Olympic Steel, Unity Bancorp, and Shore Bancshares
ACCESSWIRE - Mon Jan 11, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / January 11, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Simulations Plus Inc. (NASDAQ: SLP), Olympic Steel Inc. (NASDAQ: ZEUS), Unity Bancorp Inc. (NASDAQ: UNTY) and Shore Bancshares Inc. (NASDAQ: SHBI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SLP: 8.87 (+0.50), SHBI: 11.95 (unch), ZEUS: 21.64 (+0.41), UNTY: 12.17 (-0.03)

Simulations Plus Sets Date for 1st Quarter 2016 Earnings Release and Conference Call
BusinessWire - Fri Jan 08, 12:42PM CST
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the first quarter of its 2016 fiscal year, ending November 30, 2015, with the U.S. Securities and Exchange Commission on Thursday, January 14, 2016. Dr. Ted Grasela, president, and Walt Woltosz, chairman and CEO, will host a conference call to discuss the Company's performance on January 14, 2016, at 1:15 p.m. PST / 4:15 p.m. EST.
SLP: 8.87 (+0.50)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pavlus Travel's Bucket-List Trips in High Demand for 2027

Luxury Travel is Having a Moment A fancy vacation isn't just a postcard on the wall anymore—it's now, more than ever, a box folks are itching to check off their lists. Call it a midlife shift or just the world shrugging off its pandemic blues, but high-end travelers are saying, "The time is now," and they're serious. Pavlus Travel, a top name in the lux travel space,...

HSBC Unveils $1B Tender Offer to Manage Capital Base

HSBC's Strategic Capital Maneuver Alright, let's chew on this one: HSBC's out to repurchase up to a cool billion bucks worth of its own security paper. We're talking about the $3 billion, 6% Perpetual Subordinated Contingent Convertible Securities, which can be called up as soon as May 2027. Now, they're not going all-in—the offer is capped at $1 billion, though the...

New Congressional Guide Aims to Aid Companies' Strategies

Fresh Faces, New Dynamics: Navigating the 120th Congress Wake up and smell the Capitol Hill grind, folks. We've got the 120th Congress on our hands, brimming with fresh faces and a colossal shift in the political landscape. Thanks to our pals at Marathon Strategies, we've been thrown a bone with 'Meet The Freshmen'—a nonpartisan rundown of the latest political...

TSX Surges Amid Earnings Wave and Market Momentum

TSX Soars, But What's Driving the Surge? Gotta say, when the TSX leaps over 2% in a single day, it sets the stage for two things: excitement and scrutiny. On a balmy Wednesday, Canada's stock market stood tall at 36,317.67, up 785.39 points. Wall Street joined the dance too, with the Dow kicking up by 1,543.75 points. Good vibes all around — but hang on a minute. You...

Coinhub Funded's Bold Move in Trading World

A New Name in the Trading Game Right out of Charlestown, Saint Kitts and Nevis, Coinhub Funded is making waves in the crypto prop trading world, and boy, they're not pulling any punches. They've just thrown their hat in the ring with a tantalizing offer: get your hands on a funded trading account up to $200K, and if that's not enough to get your pulse racing, they've got...

Endava Faces Class Action for Securities Violation

Endava's Legal Storm Clouds Gather Well, well, looks like Endava plc (NYSE: DAVA) has found itself knee-deep in a legal quagmire, thanks to some not-so-transparent financial antics. Investors are up in arms, and the fine folks at DJS Law Group are stepping in, filing a class action lawsuit against Endava for overstating their financial health. They allege that Endava made...

JT Mega Embraces New Leadership as Erin Denham Steps Up

A New Captain at the Helm Erin Denham's promotion to president of JT Mega is setting the stage for some fresh momentum in the food and beverage advertising world. This Minnesotan agency, nestled right there on Minnetonka Boulevard, has been an independent force for five decades. It's a sector dominated by players who often get absorbed by the behemoth holding companies,...

Workday: Dominating Cloud ERP with AI Prowess in 2026

Workday: A Force in the Cloud ERP Arena Right on! Workday's making waves again in the world of Cloud ERP. In a move that seems to defy the competition, they've locked down their spot as a Leader in the 2026 Gartner Magic Quadrant for Cloud ERP for Service-Centric Enterprises for the fifth year running. Consistency isn’t a coincidence here, folks—this is pure strategy!...

Gundry MD Unleashes MyoPeptide: A Powerhouse Supplement

Creatine Gets a Makeover with MyoPeptide Well, here we have it! Gundry MD just rolled out their newest concoction, MyoPeptide Complex, and she's not your run-of-the-mill creatine shake. Blending creatine monohydrate with PeptiStrong®, a fava bean peptide, plus a couple of vitamins, this new supplement claims to turbocharge strength, recovery, and even your cognitive...

Fedora and Clarion Boost Oncology Practice Performance

Hell of a Pair-Up: Fedora and Clarion Focus on Oncology Well, here's a setup that doesn't scream about blue chip stocks—but it's swimming in opportunity all the same. Fedora Healthcare Solutions just shook hands with Clarion, cementing a deal that's piqued my interest for its potential to green-light some real progress for independent oncology practices. These are not...